Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ALLO - Allogene Therapeutics, Inc.
Market Cap 684M P/E - EPS this Y 27.80% Ern Qtrly Grth -
Income -279.42M Forward P/E -2.01 EPS next Y 2.60% 50D Avg Chg -10.00%
Sales 65k PEG -1.80 EPS past 5Y - 200D Avg Chg -30.00%
Dividend N/A Price/Book 1.26 EPS next 5Y 1.00% 52W High Chg -73.00%
Recommedations 2.00 Quick Ratio 11.97 Shares Outstanding 209.11M 52W Low Chg 9.00%
Insider Own 17.48% ROA -23.88% Shares Float 152.10M Beta 0.83
Inst Own 80.69% ROE -49.11% Shares Shorted/Prior 39.19M/39.23M Price 4.69
Gross Margin - Profit Margin - Avg. Volume 2,616,766 Target Price 9.59
Oper. Margin -416,624.60% Earnings Date Oct 31 Volume 2,684,209 Change -2.09%
Healthcare | Biotechnology | United States
About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics, Inc. News
12/16/24 Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/12/24 Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
12/02/24 Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?
11/25/24 Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why
11/19/24 Allogene Therapeutics Announces Participation in December Investor Conferences
11/18/24 Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
11/14/24 Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
11/08/24 Allogene's Q3 Loss Narrower Than Expected, Sales Nil
11/08/24 Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ...
11/07/24 Allogene Therapeutics: Q3 Earnings Snapshot
11/07/24 Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
11/07/24 CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
11/07/24 Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
11/05/24 Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/04/24 Allogene Therapeutics Announces Participation in November Investor Conferences
11/01/24 Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline
10/31/24 Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know
10/30/24 Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
10/29/24 We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
10/29/24 Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Mayo Stephen Director Director Aug 07 Sell 4.2855 10,000 42,855 25,328 08/09/23
Bhavnagri Veer General Counsel General Counsel Jan 17 Sell 7.04 3,000 21,120 580,677 01/18/23
WITTE OWEN N. Director Director Aug 11 Sell 16.88 15,000 253,200 218,271 08/15/22
Amado Rafael EVP of R&D and CMO EVP of R&D and CMO Aug 02 Sell 11.97 2,000 23,940 540,257 08/02/22
Amado Rafael EVP of R&D and CMO EVP of R&D and CMO Jun 21 Sell 11.18 2,000 22,360 544,257 06/22/22
Amado Rafael EVP of R&D and CMO EVP of R&D and CMO May 19 Sell 7.3993 11,500 85,092 546,257 05/19/22
Amado Rafael EVP of R&D and CMO EVP of R&D and CMO Mar 15 Sell 7.7090 5,169 39,848 320,119 03/17/22
Bhavnagri Veer General Counsel General Counsel Mar 15 Sell 7.6802 8,849 67,962 413,841 03/17/22
Chang David D President and CEO President and CEO Mar 15 Sell 7.6488 23,648 180,879 2,289,652 03/17/22
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Mar 15 Sell 7.6337 11,469 87,551 100,546 03/17/22
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Mar 15 Sell 7.6326 8,698 66,388 120,430 03/17/22
Kazam Joshua A Director Director Jan 12 Buy 12.60 15,000 189,000 258,885 01/14/22
Belldegrun Arie Director Director Jan 12 Buy 12.60 155,039 1,953,491 195,039 01/14/22
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Jan 19 Sell 31.82 30,000 954,600 1,152,595 01/19/21
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Nov 18 Sell 32.8 15,000 492,000 1,182,595 11/18/20
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Oct 16 Sell 41.24 15,000 618,600 1,197,595 10/16/20
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Oct 09 Option 2.27 35,264 80,049 147,879 10/09/20
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Oct 09 Sell 41 44,574 1,827,534 108,370 10/09/20
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Oct 08 Option 2.27 35,264 80,049 161,536 10/08/20
MOORE ALISON Chief Technical Offi.. Chief Technical Officer Oct 08 Sell 40 44,574 1,782,960 117,680 10/08/20
Bhavnagri Veer General Counsel General Counsel Oct 08 Option 2.27 10,000 22,700 363,902 10/08/20
Bhavnagri Veer General Counsel General Counsel Oct 08 Sell 40 10,000 400,000 353,902 10/08/20
SCHMIDT ERIC THOMAS Chief Financial Offi.. Chief Financial Officer Sep 22 Sell 35.92 15,000 538,800 1,212,595 09/22/20